Anova Cancer Care News
Anova proudly celebrates the 1,500th prostate cancer patient treated with CyberKnife, an advanced radiation therapy device that delivers stereotactic body radiation therapy.
Statement Regarding USPS Investigation of Forged ACC Documents by Ms. Caroline Zarate Boyle.
Anova Cancer Care's Chief Oncologist spoke to The Prostate Cancer Networking Group on March 19 about his expertise in diagnosing and treating prostate cancer. He was joined by Dr. Fabio Almeida, Medical Director of the Southwest PET/CT Institute.
The oncologist and medical director of Anova Cancer Care was invited to discusses his prostate cancer treatment expertise with CyberKnife at the Annual Academic Meeting of Radiation Oncology in Chengdu, Sichuan, China.
Anova is a proud sponsor of the 2015 Don’t Fear the Finger golf outing benefitting the Please Save Another (PSA) foundation and those struggling with stage 4 prostate cancer.
See why Anova Cancer Care uses CyberKnife to provide the best stereotactic radiosurgery option to treat cancer in its patients.
Positive quality of life outcomes, low side effects and brief duration of the CyberKnife treatment are particularly encouraging and significant for men weighing their many treatment options.
Despite an incredible difference PSA has made in lives of millions of men over the last 30 years, the US Preventive Services Task Force (USPSTF) recently recommended against using it to screen men for prostate cancer due to an increase in the proportion of men diagnosed higher-risk prostate cancers, false-positive readings and potential stress.